CLSA Wire

Precision medicine uses some of the world’s most sophisticated technologies to find the root causes of each patient’s unique condition and apply the best, most precise treatments. California is a biomedical juggernaut, and the precision medicine research being funded today will impact patients around the world. Learn how California is leading the way in precision medicine research.

On Sept. 19, House Speaker Nancy Pelosi (D-San Francisco) unveiled legislation in the form of the Lower Drug Costs Now Act (H.R. 3), an unprecedented sweeping proposal that would transfer most domestic drug pricing decision-making to U.S. and European government bureaucrats, and eviscerate the free market model that has promoted innovation, cures and treatments for millions of patients.

CLSA President & CEO Mike Guerra pens an op-ed in Morning Consult regarding the dangers of policymakers utilizing foreign price controls to lower drug costs. With growing bipartisan support for these schemes, CLSA is working to educate policymakers that importing price controls will do little to lessen the financial burden for patients. Rather, these short-sighted proposals will hinder access to needed treatments and discourage medical innovation in California.

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Senator Lena Gonzalez (D-Long Beach). We look forward to working with Senator Gonzalez and her team to advance policies that improve patient health and bring positive change for California patients and their families.

While fewer bills directly targeting the biopharmaceutical industry were introduced this year, which was likely due in large part to Governor Newsom’s executive order on state prescription purchasing, CLSA strongly supported several bills that reached the Governor’s desk and helped prevent a number of bills of concern from reaching his desk.